CVM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CEL-SCI Corp (CVM) is not a strong buy for a beginner investor with a long-term focus at this time. The stock's technical indicators are bearish, and the company is undergoing a dilutive share offering, which could pressure the stock price further. While there are some positive developments, such as the agreement with Amarox for commercialization in Saudi Arabia, the lack of strong financial performance data and no recent trading signals suggest a cautious approach.
The MACD is positive and expanding, indicating potential bullish momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting a downtrend. Key support levels are at $1.025 and $0.905, with resistance at $1.218 and $1.411.
Agreement with Amarox for the commercialization of Multikine in Saudi Arabia, targeting a growing immunotherapy market.
Potential short-term price increase based on historical candlestick pattern analysis.
Recent announcement of a dilutive share offering at $1 per share, which has already caused a decline in stock price.
Lack of significant insider or hedge fund activity.
No recent Congress trading data or strong trading sentiment.
No financial performance data is available for analysis. The company is raising $2.5 million to fund the development of its Multikine cancer drug.
No recent analyst rating or price target changes are available for CEL-SCI Corp.
